CL2023001596A1 - Composiciones y métodos para el tratamiento de enfermedades oculares - Google Patents

Composiciones y métodos para el tratamiento de enfermedades oculares

Info

Publication number
CL2023001596A1
CL2023001596A1 CL2023001596A CL2023001596A CL2023001596A1 CL 2023001596 A1 CL2023001596 A1 CL 2023001596A1 CL 2023001596 A CL2023001596 A CL 2023001596A CL 2023001596 A CL2023001596 A CL 2023001596A CL 2023001596 A1 CL2023001596 A1 CL 2023001596A1
Authority
CL
Chile
Prior art keywords
compositions
methods
treatment
eye diseases
age
Prior art date
Application number
CL2023001596A
Other languages
English (en)
Inventor
Grover Anita
Taylor Lori
Yednock Ted
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of CL2023001596A1 publication Critical patent/CL2023001596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere en general a composiciones y métodos para prevenir, tratar o reducir el riesgo de desarrollar una enfermedad ocular (p. ej., glaucoma o degeneración macular asociada con la edad). La degeneración macular asociada con la edad puede ser atrofia geográfica.
CL2023001596A 2020-12-04 2023-06-02 Composiciones y métodos para el tratamiento de enfermedades oculares CL2023001596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063121629P 2020-12-04 2020-12-04

Publications (1)

Publication Number Publication Date
CL2023001596A1 true CL2023001596A1 (es) 2024-01-19

Family

ID=81853584

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001596A CL2023001596A1 (es) 2020-12-04 2023-06-02 Composiciones y métodos para el tratamiento de enfermedades oculares

Country Status (11)

Country Link
US (1) US20240059765A1 (es)
EP (1) EP4255485A1 (es)
JP (1) JP2023551734A (es)
KR (1) KR20230117192A (es)
CN (1) CN116782940A (es)
AU (1) AU2021391800A1 (es)
CA (1) CA3200976A1 (es)
CL (1) CL2023001596A1 (es)
IL (1) IL303289A (es)
MX (1) MX2023006591A (es)
WO (1) WO2022120137A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY175896A (en) 2013-07-09 2020-07-14 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
EP3380518A4 (en) 2015-11-24 2019-07-31 Annexon, Inc. ANTI-COMPLEMENT FACTOR C1Q FAB FRAGMENTS AND USES THEREOF
WO2023212719A1 (en) * 2022-04-29 2023-11-02 Annexon, Inc. Compositions and methods for treating ocular diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3380518A4 (en) * 2015-11-24 2019-07-31 Annexon, Inc. ANTI-COMPLEMENT FACTOR C1Q FAB FRAGMENTS AND USES THEREOF

Also Published As

Publication number Publication date
CA3200976A1 (en) 2022-06-09
IL303289A (en) 2023-07-01
AU2021391800A1 (en) 2023-06-22
US20240059765A1 (en) 2024-02-22
WO2022120137A1 (en) 2022-06-09
KR20230117192A (ko) 2023-08-07
EP4255485A1 (en) 2023-10-11
MX2023006591A (es) 2023-08-11
JP2023551734A (ja) 2023-12-12
CN116782940A (zh) 2023-09-19

Similar Documents

Publication Publication Date Title
CL2023001596A1 (es) Composiciones y métodos para el tratamiento de enfermedades oculares
Alsulaiman et al. High-power handheld blue laser-induced maculopathy: the results of the King Khaled Eye Specialist Hospital Collaborative Retina Study Group
CR10041A (es) Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
MX2021005518A (es) Modelos animales, métodos de detección y métodos de tratamiento para enfermedades o trastornos intraoculares.
BRPI0516377A (pt) inibição de rnai de ctgf para tratamento de distúrbios oculares
PH12020551766A1 (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
AR056852A1 (es) INHIBICIoN DE HIF1A INTERMEDIADO POR RNAI PARA EL TRATAMIENTO DE ANGIOGENESIS OCULAR
AU2018218696B2 (en) Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid
WO2019195761A3 (en) Pharmacological agents for treating ocular diseases
AR062395A1 (es) Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares
ECSP22086300A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
PE20220384A1 (es) Composiciones y metodos de oximetazolina para el tratamiento de trastornos oculares
BR112019022912A2 (pt) Métodos e composições para tratar doenças oculares alérgicas
EA201990752A1 (ru) Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы
BRPI0517972A (pt) ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas
EA201992356A1 (ru) Способ и композиция для лечения заболевания, связанного с сетчаткой глаза, с использованием ингибитора ccr3
CO2024007361A2 (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
Richoz et al. Crosslinking for recurrent keratoconus
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
BR112022009192A2 (pt) Composição, método para tratar uma doença ocular ou distúrbio ocular, e, uso de um composto
Ferrari et al. Reply: Corneal collagen crosslinking and herpetic keratitis
MX2023012758A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular asociada con angiogenesis.
ECSP20014569A (es) Métodos para el tratamiento de enfermedades relacionadas con tnf - alfa
MX2021008821A (es) Derivados de bis (diazirina) como foto-reticulante para el tratamiento de trastornos ectasicos de cornea.